PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...

Attruby will be available at a recommended dose of 712 mg, taken twice daily, at a list price of $18,759.12 for a 28-day ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...

Deal Could End Israel-Hezbollah Conflict That Has Lasted Over a Year Lebanon’s caretaker cabinet is expected to meet to formally approve the deal, in which it would play an essential role. Maps ...

Lockheed Martin has felt financial strain as early funding for the upcoming F-35 jets dried up, but kept working on them to avoid supply chain disruptions.

Netflix announced in April 2024 that it had officially ordered and put into production a new action thriller called Ad Vitam, which translates to To Life in English. The movie has since completed ...